[225Ac]Ac-SibuDAB for Targeted Alpha Therapy of Prostate Cancer: Preclinical Evaluation and Comparison with [225Ac]Ac-PSMA-617

In the present study, SibuDAB, an albumin-binding PSMA ligand, was investigated in combination with actinium-225 and the data were compared with those of [225Ac]Ac-PSMA-617. In vitro, [225Ac]Ac-SibuDAB and [225Ac]Ac-PSMA-617 showed similar tumor cell uptake and PSMA-binding affinities as their 177Lu...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2022-11, Vol.14 (22), p.5651
Main Authors: Busslinger, Sarah D., Tschan, Viviane J., Richard, Olivia K., Talip, Zeynep, Schibli, Roger, Müller, Cristina
Format: Article
Language:English
Subjects:
Actinium
Albumin
Androgens
Antigens
Biodistribution
Blood circulation
Bone marrow
Cancer therapies
Castration
Cell culture
Exocrine glands
Experiments
FDA approval
Immunocompetence
Laboratory animals
Ligands
Metastases
Patients
Prostate cancer
Radioisotopes
Side effects
Tumors
Xenografts
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!